Effect of dienogest treatment on uterine fibroid volume in patients with endometriosis or adenomyosis complicated by uterine fibroids

Table 1 Patient characteristics at baseline, n (%) or (± SD)

Characteristics	n = 113
Age (years)	40.0 (± 6.9)
Body mass index (kg/m2)	21.5 (± 3.9)
Condition
Ovarian endometriosis	42 (37.2)
Adenomyosis	41 (36.3)
Both	13 (11.5)
Endometriosis after surgery	17 (15.0)

Table 2 Dienogest treatment for 3 months

	Premedication	Post medication	Value of difference (post medication- premedication)	P value
Maximum diameter of myoma (n = 73, mm)	22.79 ± 14.52	24.84 ± 16.22	2.04	0.002
Myoma volume (n = 73, mm)	10.71 ± 21.15	15.66 ± 31.65	4.96	0.001
Uterine volume (n = 73, mm3)	139.56 ± 89.68	142.38 ± 90.56	2.82	0.686
Maximum diameter of adenomyoma (n = 30, mm)	44.7 ± 13.57	45.97 ± 16.38	1.27	0.471
Adenomyoma volume (n = 30, mm3)	42.09 ± 33.27	47.15 ± 46.06	5.19	0.443
Maximum diameter of the cyst (n = 40, mm)	33.48 ± 13	31.13 ± 11.47	-2.35	0.134
Volume of the cyst (n = 40, mm3)	18.18 ± 20.33	12.74 ± 12.06	-5.45	0.022
Endometrial thickness (n = 73, mm)	5.93 ± 3.27	4.48 ± 2.14	-1.45	< 0.001

Table 3 Dienogest treatment for 6 months

	Premedication	Post medication	Value of difference (post medication- premedication)	P value
Maximum diameter of myoma (n = 83, mm)	23.34 ± 13.63	25.73 ± 15.13	2.40	< 0.001
Myoma volume (n = 83, mm)	10.22 ± 16.83	13.53 ± 19.78	3.31	< 0.001
Uterine volume (n = 83, mm3)	147.06 ± 102.17	144.14 ± 108.64	-2.92	0.67
Maximum diameter of adenomyoma (n = 34, mm)	46.97 ± 14.99	44.68 ± 16.48	-2.3	0.19
Adenomyoma volume (n = 34, mm3)	47.82 ± 40.38	44.61 ± 51.88	-3.21	0.59
Maximum diameter of the cyst (n = 44, mm)	35.48 ± 11.74	27.23 ± 12.31	-8.25	< 0.001
Volume of cysts (n = 44, mm3)	19.02 ± 19.48	9.99 ± 12.79	-9.02	< 0.001
Endometrial thickness (n = 83, mm)	5.89 ± 3.2	4.24 ± 1.94	-1.65	< 0.001
CA125 (n = 13, U/mL)	45.9 ± 19.5	28.2 ± 16.8	-17.7	0.006

CA125: Antigen 125.

Table 4 Dienogest treatment for 12 months

	Premedication	Post medication	Value of difference (post medication- premedication)	P value
Maximum diameter of myoma (n = 66, mm)	24.05 ± 13.55	27.08 ± 17.3	3.03	0.017
Myoma volume (n = 66, mm)	10.31 ± 15.01	17.15 ± 25.22	6.84	0.002
Uterine volume (n = 66, mm3)	141.64 ± 98.63	143.71 ± 99.65	2.07	0.797
Maximum diameter of adenomyoma (n = 26, mm)	42.5 ± 14.15	41.46 ± 19.48	-1.04	0.616
Adenomyoma volume (n = 26, mm3)	39.11 ± 36.22	37.55 ± 37.77	-1.57	0.618
Maximum diameter of the cyst (n = 38, mm)	33.11 ± 12.08	21.13 ± 15.5	-11.97	< 0.001
Volume of cysts (n = 38, mm3)	16.22 ± 17.96	7.47 ± 8.36	-8.75	0.002
Endometrial thickness (n = 66, mm)	5.94 ± 3.59	4.49 ± 2.78	-1.55	0.006
CA125 (n = 13, U/mL)	41.6 ± 20.0	22.4 ± 10.9	-19.2	0.002

CA125: Antigen 125.

Table 5 Relief of dysmenorrhea degree and drug side effects of dienogest, n (%)

	Medication for 6 months	Medication for 12 months
Number of weight gain (n = 81)	33/81 (40.7)	28/81 (34.6)
Number of patients with remission of dysmenorrhea (n = 64)	63/64 (98.4)	64/64 (100)
Number of amenorrhea patients (n = 81)	49/81 (56.3)	56/81 (69.1)
Number of irregular vaginal bleeding (n = 81)	10/81 (12.3)	7/81 (8.6)
Number of patients with acne (n = 81)	3/81 (3.7)	2/81 (2.5)
Number of patients with breast tenderness (n = 81)	8/81 (9.9)	11/81 (13.6)
Number of patients with headache (n = 81)	4/81 (4.9)	5/81 (6.2)
Number of patients suffering from depression (n = 81)	14/81 (17.3)	16/81 (19.8)
Number of patients with decreased sexual desire (n = 81)	1/81 (1.2)	1/81 (1.2)
Number of patients with hair loss (n = 81)	9/81 (11.1)	9/81 (11.1)
Average drug tolerance score (n = 81)	9.30 ± 2.14	8.73 ± 2.51